Source

Paul-Ehrlich-Institut

3 documents · Germany

Official website →

Regulation Category Type Date

New safety concern identified for ocrelizumab regarding drug-induced liver injury; liver function monitoring recommended before and during treatment.

Paul-Ehrlich-Institut · Germany

Pharmaceuticals

Safety alert & recall 7 Oct 2026

Regeneron recalls one batch of Libtayo (Cemiplimab) 350 mg due to a sealing defect in the vial.

Paul-Ehrlich-Institut · Germany

Pharmaceuticals

Safety alert & recall 29 Jul 2026

Biotest Pharma recalls batch C795316P01 of Yimmugo (human normal immunoglobulin) 100mg/ml, 100ml vials, expiry 31.08.2028.

Paul-Ehrlich-Institut · Germany

Pharmaceuticals

Safety alert & recall 16 Sep 2026 Due 31 Aug 2028

Showing 3 of 3 tracked updates Health-tech only